ES2835499T3 - Metotrexato para la vitreorretinopatía proliferativa - Google Patents

Metotrexato para la vitreorretinopatía proliferativa Download PDF

Info

Publication number
ES2835499T3
ES2835499T3 ES15827946T ES15827946T ES2835499T3 ES 2835499 T3 ES2835499 T3 ES 2835499T3 ES 15827946 T ES15827946 T ES 15827946T ES 15827946 T ES15827946 T ES 15827946T ES 2835499 T3 ES2835499 T3 ES 2835499T3
Authority
ES
Spain
Prior art keywords
methotrexate
composition
injection
erm
vrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15827946T
Other languages
English (en)
Spanish (es)
Inventor
Dean Eliott
Tomasz P Stryjewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Eye and Ear
Original Assignee
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary filed Critical Massachusetts Eye and Ear Infirmary
Application granted granted Critical
Publication of ES2835499T3 publication Critical patent/ES2835499T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES15827946T 2014-07-30 2015-07-30 Metotrexato para la vitreorretinopatía proliferativa Active ES2835499T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462030778P 2014-07-30 2014-07-30
PCT/US2015/042951 WO2016019165A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Publications (1)

Publication Number Publication Date
ES2835499T3 true ES2835499T3 (es) 2021-06-22

Family

ID=55218325

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15827946T Active ES2835499T3 (es) 2014-07-30 2015-07-30 Metotrexato para la vitreorretinopatía proliferativa
ES20191599T Active ES2969374T3 (es) 2014-07-30 2015-07-30 Metotrexato para la vitreorretinopatía proliferativa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20191599T Active ES2969374T3 (es) 2014-07-30 2015-07-30 Metotrexato para la vitreorretinopatía proliferativa

Country Status (6)

Country Link
US (4) US10098884B2 (enExample)
EP (3) EP4311575A3 (enExample)
JP (3) JP7097181B2 (enExample)
CA (2) CA3200870A1 (enExample)
ES (2) ES2835499T3 (enExample)
WO (1) WO2016019165A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7097181B2 (ja) * 2014-07-30 2022-07-07 マサチューセッツ アイ アンド イヤー インファーマリー 増殖性硝子体網膜症用メトトレキサート
US20200179392A1 (en) * 2016-08-05 2020-06-11 Schepens Eye Research Institute Idelalisib for Treating Proliferative Vitreoretinopathy and Abnormal Intraocular Neovascularization
EP3710008A4 (en) 2017-11-14 2021-08-25 The Schepens Eye Research Institute, Inc. RUNX1 INHIBITION FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND DISEASES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION
CN114423432A (zh) * 2019-09-13 2022-04-29 奥尔德拉医疗公司 甲氨蝶呤的眼用制剂
CN115804665A (zh) * 2022-12-13 2023-03-17 南昌大学附属眼科医院 一种tpvr动物模型的建立方法
WO2024129979A1 (en) * 2022-12-14 2024-06-20 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032734A1 (en) 2000-07-26 2002-03-14 Rhoads Geoffrey B. Collateral data combined with user characteristics to select web site
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US20040253243A1 (en) 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2005095464A1 (ja) * 2004-04-02 2005-10-13 Denki Kagaku Kogyo Kabushiki Kaisha ヒアルロン酸－メトトレキサート結合体
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
CN101890167B (zh) 2004-10-01 2017-03-01 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US20110200662A1 (en) 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US20140105956A1 (en) * 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
SG11201503637SA (en) * 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
JP7097181B2 (ja) * 2014-07-30 2022-07-07 マサチューセッツ アイ アンド イヤー インファーマリー 増殖性硝子体網膜症用メトトレキサート

Also Published As

Publication number Publication date
JP7097181B2 (ja) 2022-07-07
US10828306B2 (en) 2020-11-10
US10098884B2 (en) 2018-10-16
CA3200870A1 (en) 2016-02-04
US20200085827A1 (en) 2020-03-19
JP2023145527A (ja) 2023-10-11
EP3791883B1 (en) 2023-10-25
JP2017523974A (ja) 2017-08-24
EP3174540A4 (en) 2018-04-04
US20210283135A1 (en) 2021-09-16
ES2969374T3 (es) 2024-05-17
EP3791883A1 (en) 2021-03-17
US20170216294A1 (en) 2017-08-03
EP4311575A2 (en) 2024-01-31
EP4311575A3 (en) 2024-04-03
JP2021059554A (ja) 2021-04-15
US10272089B2 (en) 2019-04-30
EP3174540B9 (en) 2021-05-05
EP3174540A1 (en) 2017-06-07
WO2016019165A1 (en) 2016-02-04
EP3174540B1 (en) 2020-09-02
CA2991921C (en) 2023-08-08
US20170368067A1 (en) 2017-12-28
CA2991921A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
ES2835499T3 (es) Metotrexato para la vitreorretinopatía proliferativa
Jaffe et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device
US7083803B2 (en) Ocular solutions
Sanborn et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device
ES2326550T3 (es) Uso de un macrolido para restablecer la sensacion corneal.
Wadood et al. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification
US20060228394A1 (en) Ocular solutions
Eperon et al. A biodegradable drug delivery system for the treatment of postoperative inflammation
JP2024103501A (ja) 被験体における虚血再灌流障害のリスクを予防又は軽減するための神経保護特性がある薬物の使用
İnan et al. Prevention of posterior capsule opacification by retinoic acid and mitomycin
US20110150967A1 (en) Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
KR102860024B1 (ko) 이나보글리플로진을 포함하는 안질환의 예방 또는 치료용 약학적 조성물
HK40049263A (en) Methotrexate for proliferative vitreoretinopathy
HK40049263B (en) Methotrexate for proliferative vitreoretinopathy
HK1236395B (en) Methotrexate for proliferative vitreoretinopathy
HK1236395A1 (en) Methotrexate for proliferative vitreoretinopathy
US11260104B2 (en) Carrier composition for eye drops and pharmaceutical composition including the same
Khodakiya et al. Implants and Inserts in Diagnosis and Treatment of Macular Degeneration
CN1802151A (zh) 用于治疗病理性眼内血管生成的非甾体类抗炎药制剂
AU2013245543A1 (en) Intraocular drug delivery device and associated methods